Noxopharm Ltd. · ASX:NOX
Noxopharm — Investor Presentation (June 2021)
14 slides from Noxopharm's investor presentation, Jun 28, 2021
Slide 1: Noxopharm Corporate Presentation ASX Announcement
For personal use only Noxopharm Limited (ASX:NOX) | ASX Announcement | 28 June 2021 Noxopharm Corporate Presentation Sydney 28 June 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to provide the attached Corporate Presentation ahead of investor present
Slide 2: Forward Looking Statements
“continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about c
Slide 3: Delivering Science. Transforming Lives
For personal use only Delivering Science. Transforming Lives NOXOPHARM CORPORATE PRESENTATION JUNE 2021 Discover Dr Graham Kelly Develop CEO and Managing Director NOXOPHARM LIMITED (ASX:NOX) Deliver NOXOPHARM LIMITED 1 PRESENTATION: JUNE 2021
Slide 4: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Noxopharm Limited (NOX or the Company). It Although the Company believes that the expectations reflected in the forward looking should not be considered as an offer or invitation to subscribe for, or purchase any statements incl
Slide 5: What Distinguishes Noxopharm
WHAT DISTINGUISHES NOXOPHARM (ASX:NOX) For personal use only A technology platform offering multiple opportunities – not isolated high-risk drug opportunities A platform offering a revolutionary concept in therapeutics A platform offering outcomes highly sought in the industry A platform we own outr
Slide 6: Four R&D Businesses in One Company
FOUR R&D BUSINESSES IN ONE COMPANY For personal use only Veyonda® Cancer Research Veyonda® Pipeline Chronic inflammatory Cancer treatment Cancer growth Septic shock diseases/autoimmune enhancement factor inhibitors diseases NOXOPHARM LIMITED 4 PRESENTATION: JUNE 2021
Slide 7: Veyonda - Cancer Treatment Enhancement
1. VEYONDA® - CANCER TREATMENT ENHANCEMENT For personal use only IONIC - checkpoint inhibitor therapy DARRT - radiotherapy A revolutionary concept in cancer therapy involving a Programs drug (Veyonda®) with multiple mechanisms of action that CEP - chemotherapy boosts the effectiveness of other stand
Slide 8: Cancer Research Pipeline - Cancer Growth Factor Inhibitors
2. CANCER RESEARCH PIPELINE - For personal use only CANCER GROWTH FACTOR INHIBITORS Brain cancer (GBM) Programs Many cancers, particularly the Pancreatic cancer highly aggressive cancers, co- opt supporting healthy cells to supply growth factors that drive cancer cell growth. NOX has identified a no
Slide 9: Veyonda - Septic Shock
3. VEYONDA® - SEPTIC SHOCK For personal use only Inhibition of cytokine release syndrome Programs COVID-19 Cytokine release syndrome (CRS) is an inappropriately excessive immune response to viral and bacterial infections Sepsis generally Abnormal activation of STING signalling (response to tissue da
Slide 10: Pharmorage - Chronic Inflammatory Diseases/Autoimmune Diseases
4. PHARMORAGE - CHRONIC INFLAMMATORY For personal use only DISEASES/ AUTOIMMUNE DISEASES Chronic inflammation Pharmorage, a collaboration Programs between NOX and Hudson Institute of Medical Research, has identified a new family of Autoimmunity drug compounds with highly selective activity against S
Slide 11: Our Management
OUR MANAGEMENT For personal use only Dr Graham Kelly BSc(Vet), BVSc, PhD Shawn van Boheemen BBus, MCom, Chief Executive Officer FCPA, JP Chief Financial Officer photo Extensive experience in the biotechnology sector. Founder of four public companies: Noxopharm Senior finance executive having held fi
Slide 12: Key Metrics and News Flow
KEY METRICS (at 23 June 2021) For personal use only News Flow (next 6 months) Market cap A$195m IONIC-1, DARRT-2 & CEP-2 start patient recruitment Share price A$0.68c COVID-19 clinical trial completion Novel drug pipeline progress Issued shares ~288.2m Pharmorage progressing novel drug development f
Slide 13: Our Value Proposition
OUR VALUE PROPOSITION For personal use only What drug development companies rarely tell you We are significantly de-risked Not limited to a Multiple shots on single therapeutic goal field Aim is to assist existing therapies, Areas of major not rely on the test medical need and drug carrying the full
Slide 14: For Further Information
For personal use only FOR FURTHER INFORMATION: info@noxopharm.com Discover www.noxopharm.com Develop @Noxopharm Deliver NOXOPHARM LIMITED 12 PRESENTATION: JUNE 2021